PT  - JOURNAL ARTICLE
AU  - Cunningham, Muriel
ED  - Lewis, Eldrin F.
TI  - Neutral Results Obtained in the ELIXA Trial
DP  - 2015 Nov 21
TA  - MD Conference Express
PG  - 14--14
VI  - 15
IP  - 28
4099  - http://mdc.sagepub.com/content/15/28/14.2.short
4100  - http://mdc.sagepub.com/content/15/28/14.2.full
AB  - ELIXA was a randomized, double-blind, placebo-controlled trial among patients with type 2 diabetes mellitus who had experienced a recent acute coronary syndrome event. Lixisenatide was not superior to placebo in the primary composite end point of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for unstable angina.